The number of active drug shortages has declined sharply since June, according to the FDA’s database.
As of March 19, 76 drugs are in shortage, down from 194 in mid-June.
The database is updated daily to reflect manufacturing recoveries, regulatory actions and how shortages are classified — not solely day-to-day availability at the hospital level.
Here are 8 recent drug shortages, according to the FDA database:
- Plerixafor injection: Fresenius Kabi discontinued the 24-mg/1.2 mL (20 mg/mL) presentation of the hematology drug as a business decision on March 13.
- Peritoneal dialysis solution: Fresenius Medical Care discontinued multiple Delflex dextrose-based solutions due to NDC code changes, affecting several low magnesium/low calcium formulations used in renal care.
- Everolimus tablets: Endo, Teva and Mylan (Viatris) discontinued multiple strengths of the transplant drug across several presentations due to manufacturing decisions.
- Clindamycin palmitate hydrochloride injection: Amneal Pharmaceuticals discontinued the 75-mg/5 mL formulation of the anti-infective Feb. 27.
- Itraconazole capsules: Janssen discontinued multiple 100-mg presentations of Sporanox, an antifungal medication, Feb. 27.
- Clindamycin hydrochloride capsules: Pfizer discontinued multiple strengths (75 mg, 150 mg and 300 mg) of Cleocin capsules Feb. 25.
- Lincomycin hydrochloride injection: Pfizer discontinued Lincocin injection (2-mL multiple-dose vial) Feb. 25.
- Oxaliplatin injection: Fresenius Kabi discontinued multiple 5-mg/mL oncology formulations as a business decision, adding to prior discontinuations from other manufacturers.
The post 8 drugs in shortage appeared first on Becker's Hospital Review | Healthcare News & Analysis.
Source: Read Original Article
